• Increased cash receipts from customers in Q4 2025
• Successful operational restructuring and cost optimizations
• Raised $6.5m from share placement and entitlement offer
• Anticipating $1.5m R&D tax incentive refund in Q1 2026

Cardiex Ltd has released its June quarterly Appendix 4C, providing an update on the company's financial performance and cash flow position. The key highlights include:- Increased cash receipts from customers in Q4 2025, totaling $1.076 million, up from $3.427 million for the full year. This was driven by the first full quarter of sales of the CONNEQT Pulse and App, a new revenue source for the company.- Successful operational restructuring and cost optimization efforts, which have reduced the company's cost base by approximately 30%. This has contributed positively to cash flow in Q4, with the full benefits expected to be realized in FY26.- During the quarter, the company raised $6.5 million from a Share Placement and Entitlement Offer (before costs), with $5.37 million received in Q4 and a further $1.2 million expected in Q1 2026.- The company also increased the facility limit on its R&D Term Loan Facility with Mitchell Asset Management Pty Ltd, resulting in an additional $446,000 drawdown.- Cardiex is anticipating an additional Research and Development refund of $1.5 million in or around October 2025, from which part of the proceeds will be used to fully repay the company's R&D finance facility.

Cardiex is anticipating an additional Research and Development refund of A$1.5 million in or around October 2025.

The company believes that if required, it has the ability to raise additional capital on a timely basis and has a proven capability of doing so. The increasing sales revenue, from new and existing sources, and streamlining of operations, with significant expense base reductions, are delivering improved cash flow, initially reducing negative cash flow and then subject to performance enabling a move to positive cash flow.